Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian stock markets open firm
Tue, 7 Feb 09:30 am

Asian stock markets have opened the day on a mixed note with stock markets in South Korea (up 0.2%) and Singapore (up 0.1%) trading in the green. However, markets in China (down 1.9%) and Indonesia (down 1%) are facing selling pressure. The Indian stock markets have opened the day on a firm note. Stocks in the oil & gas and healthcare space are leading the gains.

The BSE-Sensex is trading higher by 55 points (0.3%), while the NSE-Nifty is up by around 16 points (0.3%). Mid cap and small cap stocks are also trading in the green with the BSE Mid cap and BSE Small cap indices up by 0.3% and 0.5% respectively. The rupee is trading at 48.97 to the US dollar.

FMCG stocks have opened the day on a mixed note with Henkel India and Gillette India leading the gains. However, Hindustan Unilever Ltd (HUL) and Marico are facing selling pressure. FMCG giant HUL has announced its results for the quarter ended December 2011 (3QFY12). Net sales increased by 16.5% year-on-year (YoY) to Rs 58.5 bn during the quarter ended December 2011 (3QFY12). The growth came on account of 7.4% increase in realisations as well as 9.1% rise in volume sales. Operating margins improved from 12.4% in 3QFY11 to 15.1% in 3QFY12 as advertising and promotion costs witnessed a drop of 3%. At the bottomline level, the company's profits increased by 18% YoY to Rs 7.5 bn.

Indian pharma stocks have opened the day on a firm note with Indoco Remedies and J B Chemicals leading the gains. Piramal Healthcare has recently increased its stake in Vodafone to 11% and will now have "customary rights" due to its stake. This would include a board seat in Vodafone India. Mr Ajay Piramal said that the company will appoint Mr Rajesh Laddha, CFO of Piramal Healthcare to be a part of the board of Vodafone India. Piramal with not interfere in the functioning of the company and management will be with the Vodafone management. Mr Piramal also reiterated its strategy of investing for a shorter term in companies based in India with a good record and banking on India's growth story. The company expects returns in the range of 17-20% on this investment. Piramal Healthcare will look to exit the Vodafone India stake in the next 12 to 18 months period.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian stock markets open firm". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.